The settlement, reached June 26, prohibits the company from promoting opioids through any means and bans lobbying about opioid products at the federal, state and local levels.
The last time Johnson & Johnson marketed opioids in the U.S. was 2015, and the drugmaker said it discontinued its opioid business in 2020.
To resolve claims that it fueled the opioid epidemic, Johnson & Johnson will pay New York $230 million over nine years. It will also pay an additional $30 million in the first year New York’s executive chamber signs into law new legislation to create an opioid settlement fund.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.